Category «Phase 2»

Vidofludimus

Vidofludimus 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid 1-Cyclopentene-1-carboxylic acid, 2-[[(3-fluoro-3′-methoxy[1,1′-biphenyl]-4-yl)amino]carbonyl]- [ACD/Index Name] 2-[(3-Fluoro-3′-methoxy-4-biphenylyl)carbamoyl]-1-cyclopentene-1-carboxylic acid 2-[(3-Fluoro-3′-methoxybiphenyl-4-yl)carbamoyl]cyclopent-1-ene-1-carboxylic acid 355.4 g/mol, C20H18FNO4 CAS 717824-30-1 4SC-101 UNII-8Y1PJ3VG81 SC12267 Vidofludimus calcium anhydrous RN: 1354012-90-0 UNII: FW5VY7926X IM-90838 IMU-838 Molecular Formula, 2C20-H17-F-N-O4.Ca, Molecular Weight, 748.7886 1-Cyclopentene-1-carboxylic acid, 2-(((3-fluoro-3′-methoxy(1,1′-biphenyl)-4-yl)amino)carbonyl)-, calcium salt (2:1) Inflammatory Bowel Disease, Immunosuppressants Multiple Sclerosis, Rheumatoid Arthritis, Liver and Biliary Tract Disorders, Antipsoriatics Systemic Lupus Erythematosus, Dihydroorotate Dehydrogenase (DHODH) Inhibitors …

Ritlecitinib, PF 06651600

Ritlectinib PF-06651600 CAS 1792180-81-4 C₁₅H₁₉N₅O, 285.34, UNII-2OYE00PC25 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate PF-06651600 malonate CAS: 2140301-97-7 (malonate) Chemical Formula: C18H23N5O5 Molecular Weight: 389.412 PHASE 2 alopecia areata, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. PF-06651600 is a potent and selective JAK3 inhibitor. PF-06651600 is a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and …

Fluazolepali, 氟唑帕利 , Fluzoparib

Fluazolepali CAS 2170504-09-1 Fluzoparib; SHR-3162, (HS10160) HS 10160 SHR 3162 An orally available inhibitor of poly(ADP-ribose) polymerase 1 and 2 (PARP-1/2) for treatment of solid tumors (Jiangsu Hengrui Medicine Co. Ltd., Lianyungang, China) Fluazolepali, developed by Hengrui and Howson, is intended for the treatment of recurrent ovarian cancer, triple-negative breast cancer, advanced gastric cancer and …

Tanzisertib

Tanzisertib CAS 899805-25-5 trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol C21-H23-F3-N6-O2, 448.4467 9557 Cyclohexanol, 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-, trans- CC 930 CC-930 Tanzisertib UNII-M5O06306UO A c-Jun amino-terminal kinase inhibitor.UNII, M5O06306UO Treatment of Idiopathic Pulmonary Fibrosis (IPF) Originator Celgene Corporation Class Antifibrotics; Small molecules Mechanism of ActionJ NK mitogen-activated protein kinase inhibitors Orphan Drug Status Yes – Idiopathic pulmonary fibrosis Discontinued Discoid lupus erythematosus; Idiopathic pulmonary fibrosis 16 Jul …

Ceralasertib, AZD 6738

AZD-6738, Ceralasertib Molecular Formula C20H24N6O2S Average mass 412.509 Da CAS 1352226-88-0 [RN] 1H-Pyrrolo[2,3-c]pyridine, 4-[4-[(3R)-3-methyl-4-morpholinyl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]-2-pyrimidinyl]- 4-{4-[(3R)-3-Methyl-4-morpholinyl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]-2-pyrimidinyl}-1H-pyrrolo[2,3-c]pyridine 1H-Pyrrolo(2,3-b)pyridine, 4-(4-(1-((S(R))-S-methylsulfonimidoyl)cyclopropyl)-6-((3R)-3-methyl-4-morpholinyl)-2-pyrimidinyl)- imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-λ6-sulfane 85RE35306Z AZD-6738 UNII:85RE35306Z CAS : 1352226-88-0 (free base) 1352280-98-8 (formic acid) 1352226-97-1 (racemic) 4-[4-[1-[[S(R)]-S-Methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine AZD 6738 Ceralasertib Originator AstraZeneca; University of Pennsylvania Class Antineoplastics; Morpholines; Pyrimidines; Small molecules Mechanism of Action ATR protein inhibitors Phase II Breast cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer Phase …

HEC-68498

HEC-68498, CT-365 CAS 1621718-37-3 C20 H13 F2 N5 O3 S 441.41 Benzenesulfonamide, N-[5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluoro- N-[5-(3-Cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluorobenzenesulfonamide HEC Pharm , Calitor Sciences Llc; Sunshine Lake Pharma Co Ltd PHASE 1, idiopathic pulmonary fibrosis and solid tumors Phosphoinositide 3-kinase inhibitor; mTOR inhibitor Originator HEC Pharm Developer HEC Pharm; Sunshine Lake Pharma Class Anti-inflammatories; Antifibrotics; Isoenzymes Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors Phase I Idiopathic pulmonary fibrosis 22 …

SEVITERONEL, севитеронел , سيفيتيرونيل , 赛维罗奈 ,

SEVITERONEL CAS Registry Number 1610537-15-9 Molecular formulaC18 H17 F4 N3 O3, MW 399.34 1H-1,2,3-Triazole-5-methanol, α-[6,7-bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-, (αS)- (αS)-α-[6,7-Bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-1H-1,2,3-triazole-5-methanol 8S5OIN36X4 севитеронел [Russian] [INN] سيفيتيرونيل [Arabic] [INN] 赛维罗奈 [Chinese] [INN] Mechanism of ActionAndrogen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors; Steroid 17-alpha-hydroxylase modulators WHO ATC codeL01 (Antineoplastic Agents)L01X-X (Other antineoplastic agents) EPhMRA codeL1 (Antineoplastics)L1X9 (All other antineoplastics) 1H-1,2,3-Triazole-5-methanol, alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (alphaS)- Seviteronel (developmental codes VT-464 and, formerly, INO-464) is an experimental …

CT-1812

CT-1812 Elayta Condition(s): Alzheimer’s Disease U.S. FDA Status: Alzheimer’s Disease (Phase 2) Company: Cognition Therapeutics Inc. CAS: 1802632-22-9 Chemical Formula: C24H33NO4S Molecular Weight: 431.591 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol Phenol, 4-[3-[1,3-dihydro-5-(methylsulfonyl)-2H-isoindol-2-yl]-3-methylbutyl]-2-(1,1-dimethylethoxy)- Originator Cognition Therapeutics Class Antidementias; Neuroprotectants; Nootropics; Small molecules Mechanism of Action Sigma-2 receptor antagonists Phase II Alzheimer’s disease Phase I Cognition disorders 21 Feb 2019 Cognition Therapeutics receives patent for a composition of matter patent …

Aclimostat

Aclimostat CAS: 2082752-83-6 Chemical Formula: C26H42N2O6 Molecular Weight: 478.63 Elemental Analysis: C, 65.25; H, 8.85; N, 5.85; O, 20.06 ZGN-1061; ZGN1061; ZGN 1061; Aclimostat, UNII-X150A3JK8R X150A3JK8R (3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3- methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl 3-[2-(morpholin-4-yl)ethyl]azetidine-1-carboxylate 1-Azetidinecarboxylic acid, 3-[2-(4-morpholinyl)ethyl]-, (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester 3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1- oxaspiro[2.5]octan-6-yl 3-(2-morpholinoethyl)azetidine-1-carboxylate ZAFGEN, PHASE 2, DIABETES Aclimostat, also known as ZGN-1061, is an anti-diabetic, anti-obesity MetAP2 inhibitor. Over 1.1 billion …

Cavosonstat (N-91115)

Cavosonstat (N-91115) CAS 1371587-51-7 C16H10ClNO3, 299.71 g/mol UNII-O2Z8Q22ZE4, O2Z8Q22ZE4, NCT02589236; N91115-2CF-05; SNO-6 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid Treatment of Chronic Obstructive Pulmonary Diseases (COPD), AND Cystic fibrosis, Nivalis Therapeutics, phase 2 The product was originated at Nivalis Therapeutics, which was acquired by Alpine Immune Sciences in 2017. In 2018, Alpine announced the sale and transfer of global rights to Laurel Venture Capital for further …